HDL Cholesterol: Physiology, Pathophysiology, and Management

Gordon, 1977, High-density lipoprotein as a protective factor against coronary heart disease: the Framingham study, Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9 Gordon, 1989, High-density lipoprotein and cardiovascular disease, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 354, 937, 10.1016/S0140-6736(04)17018-9 Johnson, 1993, Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination surveys, JAMA, 269, 3002, 10.1001/jama.269.23.3002 Rubins, 1995, Distribution of lipids in 8500 men with coronary artery disease, Am J Cardiol, 75, 1196, 10.1016/S0002-9149(99)80761-9 Sacks, 2002, Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors, Circulation, 105, 1424, 10.1161/01.CIR.0000012918.84068.43 Goulinet, 1997, Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon caretenoids, Arterioscler Thromb Vasc Biol, 17, 786, 10.1161/01.ATV.17.4.786 Navab, 2004, The oxidation hypothesis of atherogenesis; the role of oxidized phospholipids and HDL, J Lipid Res, 45, 993, 10.1194/jlr.R400001-JLR200 Gordon, 1989, High-density lipoprotein—the clinical implications of recent studies, N Engl J Med, 321, 1311, 10.1056/NEJM198911093211907 Yancey, 2003, Importance of different pathways of cellular cholesterol efflux, Arterioscler Vasc Biol, 23, 712, 10.1161/01.ATV.0000057572.97137.DD Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular efflux to high densiy lipoproteins, Proc Natl Acad Sci USA, 101, 9774, 10.1073/pnas.0403506101 Barter, 2006, Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease, J Am Coll Cardiol, 47, 492, 10.1016/j.jacc.2005.09.042 Williams, 1999, Scavenger receptor B1 and cholesterol trafficking, Curr Opin Lipid, 10, 329, 10.1097/00041433-199908000-00007 Schwartz, 2004, Lipoprotein cholesteryl ester production, transfer and output in humans, J Lipid Res, 45, 1594, 10.1194/jlr.M300511-JLR200 Puchois, 1987, Apolipoprotein A-I containing lipoproteins in coronary artery disease, Atherosclerosis, 68, 35, 10.1016/0021-9150(87)90091-8 Huang, 1995, Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma, Arterioscler Thromb Vasc Biol, 15, 1412, 10.1161/01.ATV.15.9.1412 Fan, 1991, HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction, Circulation, 84, 129, 10.1161/01.CIR.84.1.129 Asztalos, 2005, Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial, Arterioscler Thromb Vasc Biol, 25, 2185, 10.1161/01.ATV.0000183727.90611.4f Yla-Herttuala, 1999, Oxidized LDL and atherogenesis, Ann NY Acad Sci, 874, 134, 10.1111/j.1749-6632.1999.tb09231.x Parthasarathy, 1990, High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein, Biochim Biophys Acta, 1044, 275, 10.1016/0005-2760(90)90314-N Navab, 2001, HDL and the inflammatory response induced by LDL-derived oxidized phospholipids, Arterioscler Thromb Vasc Biol, 21, 481, 10.1161/01.ATV.21.4.481 Galle, 1994, Oxidized lipoproteins inhibit endothelium-dependent vasodilation, Hypertension, 23, 556, 10.1161/01.HYP.23.5.556 Libby, 2002, Inflammation and atherosclerosis, Circulation, 1135, 10.1161/hc0902.104353 Dimayuga, 1999, Reconstituted HDL containing apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice, Biochem Biophys Res Commun, 264, 465, 10.1006/bbrc.1999.1278 Cockerill, 2001, Elevation of plasma high-density lipoprotein concentration reduces interleukin-1 induced expression of E-selectin in an in vivo model of acute inflammation, Circulation, 103, 108, 10.1161/01.CIR.103.1.108 Spieker, 2002, High-density lipoprotein restores endothelial function in hypercholesterolemic men, Circulation, 105, 1399, 10.1161/01.CIR.0000013424.28206.8F Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276;34480-5. Ansell, 2005, High-density lipoprotein function: recent advances, JACC, 46, 1792, 10.1016/j.jacc.2005.06.080 Yuhanna, 2001, High density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase, Nat Med, 7, 853, 10.1038/89986 Li, 2002, High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide syntase in a ceramide-dependent manner, J Biol Chem, 277, 11058, 10.1074/jbc.M110985200 Nofer, 2004, Suppression of endothelial cell apotosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids, J Clin Invest, 113, 569, 10.1172/JCI18004 Fleisher, 1982, Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins, J Biol Chem, 257, 6653, 10.1016/S0021-9258(18)34477-6 Horio, 1993, Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells, Atherosclerosis, 101, 185, 10.1016/0021-9150(93)90115-B Kuhn, 1991, Effects of high-density lipoprotein on acetylcholine-induced vasoreactivity, Am J Cardiol, 68, 1425, 10.1016/0002-9149(91)90274-O Saku, 1985, Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man, Thromb Res, 39, 1, 10.1016/0049-3848(85)90116-1 Nofer, 1998, HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate, Arterioscler Thromb Vasc Biol, 18, 861, 10.1161/01.ATV.18.6.861 Curtiss, 1984, Interaction of plasma lipoproteins with human platelets, Blood, 64, 365, 10.1182/blood.V64.2.365.365 Griffin, 1999, High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C, J Clin Invest, 103, 219, 10.1172/JCI5006 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Assmann G, von Eckardstein A, Funke H, et al. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 87;III28-34. Patel, 1998, Mapping a gene involved in regulating dietary cholesterol absorption., J Clin Invest, 102, 1041, 10.1172/JCI3963 Hobbs, 1990, The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein, Annu Rev Genet, 24, 133, 10.1146/annurev.ge.24.120190.001025 Knoblauch, 2004, Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol, Hum Mol Genet, 13, 993, 10.1093/hmg/ddh119 Hansel, 2004, Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity, J Clin Endocrinol Metab, 89, 4963, 10.1210/jc.2004-0305 Lamon-Fava, 1996, Impact of BMI on coronary heart disease risk factors in men and women; the Framingham Offspring Study, Arterioscler Thromb Vasc Biol, 16, 1509, 10.1161/01.ATV.16.12.1509 Datillo, 1992, Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis, Am J Clin Nutr, 56, 320, 10.1093/ajcn/56.2.320 Ginsberg, 1998, Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA study, protocol 1, Arterioscler Thromb Vasc Biol, 18, 441, 10.1161/01.ATV.18.3.441 Ginsberg, 2000, Nonpharmacologic management of low levels of high-density lipoprotein cholesterol, Am J Cardiol, 86, 41L, 10.1016/S0002-9149(00)01469-7 Lichtenstein, 1999, Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels, N Engl J Med, 340, 1933, 10.1056/NEJM199906243402501 Harper, 2001, The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease, Arch Intern Med, 161, 2185, 10.1001/archinte.161.18.2185 Nestel, 1984, Suppression by diets rich in fish oil of very low density lipoprotein production in man, J Clin Invest, 74, 82, 10.1172/JCI111422 Harris, 1996, N-3 fatty acids and lipoproteins: comparison of results from human and animal studies, Lipids, 31, 243, 10.1007/BF02529870 Frenais, 2001, Effect of dietary -3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus, Atherosclerosis, 157, 131, 10.1016/S0021-9150(00)00723-1 Thompson, 1990, What do muscles have to do with lipoproteins?, Circulation, 81, 1428, 10.1161/01.CIR.81.4.1428 Zmuda, 1998, Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol, Atherosclerosis, 137, 215, 10.1016/S0021-9150(97)00257-8 Hardman, 1999, Role of exercise and weight loss in maximizing LDL cholesterol reduction, Eur Heart J Suppl, 1, S123 An, 2005, Evidence of major genes for plasma HDL, LDL cholesterol and triglyceride levels at baseline and in response to 20 weeks of endurance training: the HERITAGE Family Study, Int J Sports Med, 26, 414, 10.1055/s-2004-821160 Lakier, 1992, Smoking and cardiovascular disease, Am J Med, 93, 8S, 10.1016/0002-9343(92)90620-Q Garrison, 1978, Cigarette smoking and HDL cholesterol: the Framingham Offspring Study, Atherosclerosis, 30, 17, 10.1016/0021-9150(78)90149-1 Rimm, 1999, Moderate alcohol intake and lower risk of coronary heart disease: a meta-analysis of effects on lipids and haemostatic factors, BMJ, 319, 1523, 10.1136/bmj.319.7224.1523 Lin, 1991, Effect of chronic ethanol feeding on high density lipoprotein subfractions in rats, Alcohol Clin Exp Res, 15, 207, 10.1111/j.1530-0277.1991.tb01857.x Kashyap, 2003, Optimal therapy of low levels of high density lipoprotein-cholesterol, Am J Cardiovasc Drugs, 3, 53, 10.2165/00129784-200303010-00006 Jin, 1999, Niacin accelerates intracellular ApoB degredation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells, Arterioscler Thromb Vasc Biol, 19, 1051, 10.1161/01.ATV.19.4.1051 Jin, 1997, Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells, Arterioscler Thromb Basc Biol, 17, 2020, 10.1161/01.ATV.17.10.2020 Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation, 110, 3512, 10.1161/01.CIR.0000148955.19792.8D Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Whitney, 2005, A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events, Ann Intern Med, 142, 95, 10.7326/0003-4819-142-2-200501180-00008 Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, JACC, 8, 1245, 10.1016/S0735-1097(86)80293-5 Morgan, 2003, Effects of extended-release niacin on lipoprotein subclass distribution, Am J Cardiol, 91, 1432, 10.1016/S0002-9149(03)00394-1 Probstfield, 1994, Nicotinic acid as a lipoprotein-altering agent, Arch Intern Med, 154, 1557, 10.1001/archinte.154.14.1557 Illingworth, 1994, Comparative effects of lovastatin and niacin in primary hypercholesterolemia, Arch Intern Med, 154, 1586, 10.1001/archinte.154.14.1586 Staels, 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, 98, 2088, 10.1161/01.CIR.98.19.2088 Chawla, 2001, PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway, Nat Med, 7, 53, 10.1038/83348 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Guyton, 2000, Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia, Arch Intern Med, 160, 1177, 10.1001/archinte.160.8.1177 Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 McKenney, 1999, Role of fibrates in the management of hypertriglyceridemia, Am J Cardiol, 83, 30F Schaefer, 1999, Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease, Atherosclerosis, 144, 177, 10.1016/S0021-9150(99)00053-2 Chapman, 2004, Are the effects of statins on HDL-cholesterol clinically relevant?, Eur Heart J, 6, C58, 10.1016/j.ehjsup.2004.04.002 Smilde, 2001, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial, Lancet, 357, 577, 10.1016/S0140-6736(00)04053-8 Jones, 2003, Comparison of the efficacy and safety of rosuvistatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Cannon, 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Gotto, 2000, Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), Circulation, 101, 477, 10.1161/01.CIR.101.5.477 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615 1995, Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S), Lancet, 345, 1274, 10.1016/S0140-6736(95)90926-5 http://www.clinicaltrials.gov/ct/show/NCT00120289?order=1 http://www.clinicaltrials.gov/ct/show/NCT00000620?order=4 Zetia (ezetimibe) package insert. Kenilworth, NJ: Schering Corporation, 2002. Altmann, 2004, Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption, Science, 303, 1201, 10.1126/science.1093131 Sudhop, 2002, Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia, Drugs, 62, 2333, 10.2165/00003495-200262160-00002 Ballantyne, 2003, Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial, Circulation, 107, 2409, 10.1161/01.CIR.0000068312.21969.C8 Lehmann, 1995, An antidiabetic thiazoladinedione is a high affinity ligand for peroxisome proliferators-activated receptor-gamma (PPAR-gamma), J Biol Chem, 270, 12953, 10.1074/jbc.270.22.12953 Sakamoto, 2000, Activation of human peroxisome proliferators-activated receptor (PPAR) subtypes by pioglitazone, Biochem Biophys Res Commun, 278, 704, 10.1006/bbrc.2000.3868 Nagashima, 2005, Effects of the PPAR-γ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus, J Clin Invest, 115, 1323, 10.1172/JCI200523219 Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351;11:1106-18. Szapary, 2006, Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome, Atherioscler Thromb Vasc Biol, 26, 182, 10.1161/01.ATV.0000195790.24531.4f Dormandy, 2005, Secondary prevention of macrovascular events in patients with type two diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial I macrovascular Events): a randomized control trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Goldberg, 2005, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia, Diabetes Care, 28, 1547, 10.2337/diacare.28.7.1547 Cabrero, 2003, Differential effects of peroxisome proliferator-activated receptor activators of the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages, Metabolism, 52, 652, 10.1053/meta.2003.50100 Winkler, 2003, Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study, Diabetes Care, 26, 2588, 10.2337/diacare.26.9.2588 Gerstein, 2004, Rationale, design and recruitment of a large, simple, international trial of diabetes prevention: the DREAM trial, Diabetologica, 47, 1519, 10.1007/s00125-004-1485-5 Saad, 2004, Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects, Diabetes Care, 27, 1324, 10.2337/diacare.27.6.1324 Nissen, 2005, Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus, JAMA, 294, 2581, 10.1001/jama.294.20.joc50147 Miller, 1984, Estradiol-induced alteration of very-low-density lipoprotein assembly, J Boil Chem, 259, 15277, 10.1016/S0021-9258(17)42546-4 Walsh, 1991, Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins, N Engl J Med, 325, 1196, 10.1056/NEJM199110243251702 Manson, 2003, Estrogen plus progestin and the ris of coronary heart disease, N Engl J Med, 349, 523, 10.1056/NEJMoa030808 Grey, 1995, The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women, J Clin Endocrinol Metab, 3191, 10.1210/jc.80.11.3191 Barrett-Connor, 2006, Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women, N Engl J Med, 355, 125, 10.1056/NEJMoa062462 Van Lenten, 1995, Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response, J Clin Invest, 96, 2758, 10.1172/JCI118345 Despres, 2005, Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761 Franceschini, 1998, Relationship of the phenotypic expression of apo-A-I Milano apoprotein with plasma lipid and lipoprotein patterns, Circulation, 97, 780 Gualandri, 1985, Identification of the complete kindred and evidence of a dominant genetic transmission, Am J Hum Genet, 37, 1083 Sirtori, 2001, Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda Study, Circulation, 103, 1949, 10.1161/01.CIR.103.15.1949 Franceschini, 1999, Increased cholesterol efflux potential of sera from apo-A-I Milano carriers and transgenic mice, Arterioscler Thromb Vasc Biol, 19, 1257, 10.1161/01.ATV.19.5.1257 Shah, 2001, High dose recombinant apo-A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein-e deficient mice, Circulation, 103, 3047, 10.1161/hc2501.092494 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Navab, 2004, Human apolipoprotein A-I and A-I mimetic peptides:potential for atherosclerosis reversal, Curr Opin Lipidol, 15, 645, 10.1097/00041433-200412000-00004 Brown, 1989, Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins, Nature, 342, 448, 10.1038/342448a0 Ordovas, 2000, Association of cholesteryl ester transfer protein-TaqB1 polymorphism with variations in lipoprotein subclasses and coronary heart disease ris:the Framingham study, Arteriosclerosis Vasc Biol, 20, 1323, 10.1161/01.ATV.20.5.1323 Okamato, 2000, A cholesteryl ester transfer protein attenuates atherosclerosis in rabbits, Nature, 406, 203, 10.1038/35018119 Morehouse LA. The CETP-inhibitor Torctrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at XV International Symposium on Drugs Affecting Lipid Metabolism, October 24 to 27, 2004, Venice, Italy. Rittershaus, 2000, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model or atherosclerosis, Ateriosclerosis Thromb Vasc Biol, 20, 2106, 10.1161/01.ATV.20.9.2106 Huang, 2002, Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia, Clin Sci (Lond), 103, 587, 10.1042/cs1030587 Zhong, 1996, Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels, J Clin Invest, 97, 2917, 10.1172/JCI118751 Klerkx, 2004, Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS), Eur J Clin Invest, 34, 21, 10.1111/j.1365-2362.2004.01281.x Boekholdt, 2004, Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women:the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study, Circulation, 110, 1418, 10.1161/01.CIR.0000141730.65972.95 De Grooth, 2004, The relationship between cholesteryl ester transfer protein levels and risk profile in patients with familial hypercholesterolemia, Atherosclerosis, 173, 261, 10.1016/j.atherosclerosis.2003.11.020 Davidson, 2003, The safety and immunogenicity of a CETP vaccine in healthy adults, Atherosclerosis, 169, 113, 10.1016/S0021-9150(03)00137-0 De Grooth GJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159-65. Kuivenhoven, 2005, Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia, Am J Cardiol, 95, 1085, 10.1016/j.amjcard.2004.12.064 Bisoendial, 2005, Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia, Arterioscler Thromb Vasc Biol, 25, e133, 10.1161/01.ATV.0000179009.60612.28 Clark, 2004, Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib, Arterioscler Thromb Vasc Biol, 24, 490, 10.1161/01.ATV.0000118278.21719.17 Brousseau, 2004, Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol, N Engl J Med, 350, 1505, 10.1056/NEJMoa031766 Clark, 2006, Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action, J Lipid Res, 47, 537, 10.1194/jlr.M500349-JLR200 Davison M. Efficacy and safety of a novel CETP inhibitor torcetrapib administered with and without atorvastatin in subjects with a low level of HDL-C. Am Coll Cardiol Scientific Session 2005 March 6-9 2005, Orlando, FL. Brousseau, 2005, Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion, Arterioscler Thromb Vasc Biol, 25, 1057, 10.1161/01.ATV.0000161928.16334.dd 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report, Circulation, 106, 3142 2004, American Diabetes Association Position Statement., Diabetes Care, 27, S68 Mosca, 2004, Evidence-based guidelines for cardiovascular disease prevention in women, Circulation, 109, 672, 10.1161/01.CIR.0000114834.85476.81 Harper, 1999, New perspectives on the management of low levels of high-density lipoprotein cholesterol, Arch Intern Med, 159, 1049, 10.1001/archinte.159.10.1049